12:00 AM
 | 
May 18, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Brilinta ticagrelor: Phase III data

Top-line data from the double-blind, double-dummy, international Phase III PLATO trial in 18,624 patients showed that Brilinta met the primary endpoint of significantly increasing the time to a recurrent cardiovascular event vs. Plavix clopidogrel (p-value not disclosed). Patients received twice-daily 90 mg oral Brilinta or once-daily 75 mg oral Plavix, an ADP receptor antagonist...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >